

# A chitosan-based nanosystem as pneumococcal vaccine delivery platform

Sandra Robla, Maruthi Prasanna, Rubén Varela-Calviño, Cyrille Grandjean, Noemi Csaba

## ► To cite this version:

Sandra Robla, Maruthi Prasanna, Rubén Varela-Calviño, Cyrille Grandjean, Noemi Csaba. A chitosan-based nanosystem as pneumococcal vaccine delivery platform. Drug Delivery and Translational Research, 2021, A Perspective of Drug Delivery and Translational Research in Europe, 11 (2), pp.581-597. 10.1007/s13346-021-00928-3. hal-03313326

## HAL Id: hal-03313326 https://hal.science/hal-03313326

Submitted on 3 Aug 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. 1


## A chitosan-based nanosystem as pneumococcal vaccine delivery platform

2 Sandra Robla, Maruthi Prasanna, Rubén Varela Calviño, Cyrille Grandjean & Noemi Csaba.

## 3 Abstract

Chitosan-based nanosystems have been described as interesting tools for antigen delivery and for enhancing
the immunogenicity of nasally administered vaccines. As a possible vaccine delivery method, the chemical
conjugation of chitosan nanocapsules with the *Streptococcus pneumoniae* cell membrane protein PsaA
(pneumococcal surface adhesin A) is suggested here. The antigen PsaA, common to all pneumococcus
serotypes, is expected to improve its uptake by immune cells and to activate specific T cells, generating an
adaptive immune response against pneumococcus.

10 With this aim, chitosan nanocapsules with thiol-maleimide conjugation between the polymer (chitosan) and 11 the antigen (PsaA) were designed to enable the surface presentation of PsaA for immune cell recognition. 12 Spherical shaped particles, with a size of  $266\pm32$  nm, positive charge of  $\pm30\pm1$  mV and good stability 13 profiles in simulated nasal fluids (up to 24 h) were achieved. PsaA association rates were three times higher 14 compared to nanocapsules without covalent polymer-protein conjugation. Cytotoxicity studies in cell 15 culture media showed non-toxic effect under 150 µg/mL concentration of nanocapsules, and subsequent 16 studies on the maturation of immature dendritic cells in the presence of antigen-conjugated nanocapsules 17 displayed peripheral blood mononuclear cell activation and lymphocyte differentiation after their 18 presentation by dendritic cells. Secretion of TNFa following exposure to nanocapsules and the ability of 19 nanocapsules to activate CD4 and CD8 T lymphocytes has also been studied.



21 **Graphical abstract:** Antigen loaded nanocarriers uptake and presentation by professional presenting cells.

22 Keywords: Chitosan, nanovaccine, dendritic cell, antigen protein, immune response.

## 23 1. Introduction

24 Streptococcus pneumoniae is an opportunistic pathogen that colonizes the human upper respiratory tract 25 and causes pneumonia, meningitis and septicemia [1]. It is responsible for high morbidity and mortality 26 rates, especially among infants, elderly and immunocompromised people [2]. The cell surface of S. 27 pneumoniae contains various proteins and capsular polysaccharides (CPS) that play an important role in 28 pathogen attachment and immune system evasion. The CPS diversity results in more than 96 stereotypes 29 whereas cell surface proteins are more conserved and less variable [3]. Currently available CPS-based 30 vaccines such as PCV13 and PCV10 (Pneumococcal Conjugated Vaccines) and PPSV23 (Pneumococcal 31 Polysaccharide Vaccine) only induce specific serotype dependent immune responses [4]. In addition, 32 PPSV23 lacks the ability to generate robust immune responses in high-risk populations such as infants or 33 the elderly. To address some of these obstacles, several studies investigated the possibility of using protein 34 antigens expressed at the S. pneumoniae cell wall as potential vaccine candidates. One relevant cell 35 membrane protein is Pneumococcal surface adhesin A (PsaA) [5]. PsaA is a critical factor for the 36 colonization and adhesion of the pneumococcus in nasopharyngeal epithelial cells. It has been shown to 37 activate both the humoral and cellular response of the immune system against the entry of the pathogen via 38 the respiratory airways [6].

39 Intranasal route has been extensively explored for non-invasive immunization, stimulating mucosal and 40 systemic immunity and protecting against respiratory infections [7]. The protective nasal epithelial barrier 41 presents a large surface area which produces a rapid permeation of drugs [8], as well as the NALT (Nasal 42 Associated Lymphoid Tissue), responsible for the production of long-term antigen-specific antibodies 43 [9][10]. The nasal barrier exhibits metabolic activity and is covered with a dynamic mucus layer which 44 limits the permeability of the epithelium and decreases formulation residence time [11]. In this context, 45 nanostructures have been described as interesting tools to enhance the delivery of proteins, improving the 46 immunogenicity of nasally administered vaccines [12]. Indeed, nanostructures play an important role in the 47 stimulation of an adaptive immune response, upon facilitating the antigen uptake and processing by 48 professional antigen-presenting cells such as dendritic cells (DCs) [13], and the immediate innate immune 49 response against these inhaled external substances by macrophages [14]. Chitosan (CS), a polysaccharide 50 derived from the deacetylation of chitin [15] has been widely used in the design of nanocarriers for nasal 51 absorption of peptides like insulin, salmon calcitonin, leuprolide or parathyroid hormone [16], thanks to its 52 high mucoadhesiveness, biocompatibility and biodegradability [17]. Previous studies have shown that 53 chitosan nanocapsules are good candidates for protein administration by nasal route [16], and also have 54 been reported to have an adjuvant effect by promoting innate immune responses [18]. In this research, a 55 mucoadhesive chitosan nanocarrier containing a covalently conjugated pneumococcal protein antigen was 56 designed and characterized to evaluate its capacity as a nasal drug delivery system..

#### 57 2. Materials and methods

58 Miglyol 812® was purchased from Cremer Oleo (Hamburg, Germany), polyethylene glycol stearate 40 59 (PEG-st 40) was purchased from Croda Chemicals Europe Ltd (Snaith, United Kingdom) and sodium 60 glycocholate (SGC) was obtained from Dextra laboratories Ltd (Reading, United Kingdom). Chitosan HCl 61 ((C<sub>6</sub>H<sub>11</sub>NO<sub>4</sub>Cl)<sub>n</sub>, Mw: 1526.5 g/mol, deacetylation degree of 85%) was purchased from Heppe Medical 62 Chitosan GmbH (Saale, Germany). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, 63 C<sub>8</sub>H<sub>17</sub>N<sub>3</sub>, Mw: 191.7 Da), N-Hydroxysuccinimide (NHS, C<sub>4</sub>H<sub>5</sub>NO<sub>3</sub>, Mw: 115.09 Da), sodium chloride 64 (NaCl), potassium chloride (KCl), calcium chloride hydrate (CaCl<sub>2</sub>·2H<sub>2</sub>O) and mucin type III were 65 purchased from Sigma Aldrich (MO, USA). Maleimide propionic acid 95% (m-PA, C<sub>11</sub>H<sub>10</sub>N<sub>2</sub>O<sub>6</sub>, 66 Mw:169.13 Da) and hydroxylamine were obtained from Alfa Aesar (MA, USA). Cyanine5 NHS ester dye 67 (Cy5-NHS) was provided by Lumiprobe (Hannover, Germany), S-acetylthioacetate succinimidyl ester (SATA, Mw: 231.23 Da) and the SnakeSkin<sup>TM</sup> Dialysis Tubing 3.5K MWCO were obtained from Fischer
scientific (MO, USA). The Ni-NTA resin was obtained from Macherey-Nagel, and PsaA used in the
experiments was provided by UFIP UMR CNRS 6286 at University of Nantes.

71 For in vitro experiments sterile and autoclaved material were used. Macrophage Raw 264.7 cell line was 72 obtained from ATCC (VA, USA), Ficoll-Paque<sup>™</sup> PLUS (density 1.077 g/mL) was purchased from GE 73 Healthcare Bio-Science AB (IL, USA), Roswell Park Memorial Institute medium (RPMI-1640) and 74 Dulbecco's Modified Eagle's Medium (DMEM) were obtained from GIBCO® (Thermo Fisher Scientific, 75 MA, USA). Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 4 (IL-4), 76 allophycocyanin (APC)-conjugated anti-human CD83 (CD83-APC), phycoerythrin (PE)-conjugated anti-77 human CD86 (CD86-PE) and fluorescein (FITC)-conjugated anti-human CD1a (CD1a-FITC), were 78 purchased from Miltenvi Biotec (CA, USA), anti-human CD4-APC, CD8-APC; CD25-PE and CD28-PE 79 were obtained from Tonbo Biosciences (CA, USA). Fluorescein (FITC)-conjugated anti-human CD3 80 (CD3-FITC) and phycoerythrin (PE)-conjugated anti-human Tumor Necrosis Factor alpha (TNF- $\alpha$ ) were 81 both from Miltenyi Biotec (Madrid, Spain). Fetal Bovine Serum (FBS), PSG (100 U/ml penicillin, 0.1 82 mg/ml streptomycin and 2 mM L-glutamine) and Ebioscience<sup>TM</sup> 7-aminoactinomycin D (7-AAD) viability 83 staining were purchased from Invitrogen (CA, USA). Lipopolysaccharide (LPS) from Escherichia coli and 84 Brefeldin A (BFA) were purchased from Sigma Aldrich (MO, USA). MTS (reactive de Owen (3-(4,5-85 dinetiltiazol-2-il)-5(3-carboximetoxifenil)-2-(4-sulfofenil)-2H tetrazolium) cell proliferation assay kit was provided by BioVision (CA, USA). Triton<sup>®</sup> X-100 was purchased from Scharlab (Barcelona, Spain), and 86 interferon gamma (IFNy) was purchased from Peprotech, (London, UK). All other chemicals were of 87 88 reagent grade or higher purity.

## 89 2.1. Antigen production and characterization

The mature PsaA used as an antigen was previously expressed and purified [19]. Briefly, a plasmid encoding PsaA deprived of its signal peptide was transformed into *E. coli* BL 21 cells. Fractions containing the target protein were purified by affinity chromatography and the protein was purified to eliminate any traces of endotoxin present using endotoxin removal beads.

## 94 2.2. Functionalization of the polymer and proteins and their characterization

95 2.2.1. <u>PsaA-SATA conjugation</u>

96 For functionalization of PsaA, 1.35 mg of SATA was incorporated at 45 minute-intervals for 3 times (0.45 97 mg x 3, ~40 equiv) into 5 mg/mL of PsaA antigen in PBS 0.1 M pH 7.4, at 4°C under stirring. Subsequently, 98 the reaction mixture was dialyzed in 0.1 M PBS to eliminate the excess of reagent using dialysis membrane 99 (3.5 kDa) at 4°C. The ability of the conjugated protein to retain its structural conformation was studied 100 using circular dichroism (CD) using Jasco J-810 spectropolarimeter. The baseline was obtained using a 101 blank solution containing the buffer. Solution of PsaA or the conjugated PsaA-SATA was diluted to 0.1 102 mg/mL in buffer solution and was scanned over the wavelength range 200-260 nm. The analysis was 103 performed using a 1-nm quartz cylindrical cell at a scanning speed of 50 nm/min, 0.1 nm bandwidth and a 104 temperature of 20°C. PsaA and PsaA-SATA mass spectra were also determined on an Autoflex III MALDI-105 TOF/TOF spectrometer (Bruker Daltonics).

106

## 2.2.2. <u>Chitosan-maleimide conjugation</u>

In brief, maleimide-propionic acid (0.553 mg, 5:1 ratio CS:m-PA) in dimethyl sulfoxide (DMSO) was
reacted with 5 mg of chitosan in the presence of 0.339 mg of NHS (2:1 ratio CS:NHS) and 0.188 mg of
EDC (2:1 ratio CS:EDC) as crosslinkers and were kept under constant stirring for 24 h. Excess reagents
were removed by dialysis using dialysis membrane (3.5 kDa). The chemical conjunction between chitosan
and maleimide-propionic acid was confirmed by H<sup>1</sup>-NMR spectrometry (Bruker BRX-500).

112

## 2.3. Preparation of the nanocapsules

Blank CS and CS-maleimide nanocapsules (NCs) were prepared by solvent displacement technique [20].
An organic phase of 1.6 mg of PEG st-40, 0.5 mg of SGC and 6.25 µL of Miglyol<sup>®</sup> (density 0.94 g/mol) in
a final volume of 500 µL of ethanol was poured over a 0.5 mg/mL CS (for CS NCs obtention) or CSmaleimide (for CS-maleimide NCs) solution [21], and was kept under continuous stirring for 1 h. Later, the
organic solvent was removed under vacuum using rotary evaporation (R-300 Buchi<sup>®</sup>, 150 rpm, 50 mbar, 5
min at 37°C) to a constant volume of 1 mL. Finally, nanocapsules were isolated by centrifugation
(Eppendorf 5430R<sup>®</sup>, at 20.000 g for 30 min at 4°C) and resuspended in ultrapure water.

120 The association of PsaA and PsaA-SATA was carried out at the end of the synthesis of CS and CS-121 maleimide nanocapsules, respectively, using a mass ratio of 1:5 (PsaA:polysaccharide) for the association 122 of the protein. In both cases, protein was added and kept under continuous stirring for 10 min, and to ensure 123 the entire removal of unassociated PsaA/PsaA-SATA, nanocapsules were centrifugated (10.000 g for 5 min 124 at RT). For *in vitro* studies, the conjugated NCs were labeled with the fluorescent marker Cy5. For this, Cy5-NHS in DMSO was added to CS-maleimide in acetate buffer at pH 5.6 (mass ratio 1:1) and kept overnight under magnetic stirring. Then, the reaction was stopped, and excess dye was removed using PD10 columns (Centri-Pure P10- Gel Fixing Column, Zetadex-emp Biotech GmbH, Berlin, Germany) and the purified product was dialyzed again overnight.

Optionally, NCs were freeze dried in the presence of trehalose 5% (w/v) as cryoprotectant. NCs and trehalose solution were mixed 1:1 (v/v) in a freeze-drying glass vials, they were frozen at -80°C and then transferred to the freeze-drier (Labconco Corp., USA), using a primary drying cycle from -40°C to 20°C (+10°C/step, 18h, 12h, 5h and 4x2h) and a secondary drying cycle (22°C, 3 h and -20 mTorr vacuum conditions).

135

#### 2.3.1. <u>Physicochemical characterization of nanocapsules</u>

136 The hydrodynamic diameter, polydispersity index (PDI) and derived count rate of the prepared NCs were 137 measured using dynamic light scattering (DLS). The zeta potential values were obtained by laser droppler 138 anemometry using a Zetasizer Nano-S (Malvern Instruments; Malvern, UK). The NCs were diluted 1:20 in 139 ultrapure water (MilliQ<sup>®</sup>, Merck, NJ, USA) prior to the measurement. Analysis was performed in triplicate 140 at 25°C with a detection angle of 173° in ultrapure water. Nanoparticle tracking analysis (NTA) was used 141 to measure the particle size of NCs based on imaging after dilution in ultrapure water using a NanoSight 142 NS3000 equipment (Malvern analytical Ltd., Malvern, UK). For NTA analysis CS NCs were diluted 1:100 143 to keep the concentration within the instrument measuring range.

## 144 2.3.2. <u>Association efficiency</u>

The association efficiency (AE%) of protein was estimated by quantifying the difference in absorbance of
the total amount of protein and the amount of free protein present in the supernatant after centrifugation.
The free protein in the supernatant was analyzed by Micro BCA assay colorimetric method (Micro BCA
Protein Assay, Thermofisher Scientific, Spain) using a microplate reader (Synergy H1 Hybrid Multi-Mode,
BioTek, Winooski, VT) by measuring the absorbance at 562 nm.

## 150 2.3.3. <u>Morphological characterization</u>

151 The surface morphology of the nanocapsules was studied using FESEM and STEM electron microscopy

152 (FESEM Ultra Plus, ZEISS, Germany). For FESEM studies, 10 µL of the diluted sample was placed on the

silicon wafer and kept in the desiccator overnight for drying. Before the analysis, the samples were sputter

coated with iridium in an argon atmosphere. For STEM studies, NCs were also diluted 1:100 and 10 µL
was placed on copper grids with carbon films and then washed drop-by-drop with water. Later the grids
were air dried overnight in the desiccator and the analysis was performed.

#### 157 2.3.4. <u>Colloidal stability</u>

158 The colloidal stability of the antigen loaded nanocapsules before and after freeze drying procedure was 159 studied in vitro using Simulated Nasal Fluid (SNF), composed of 7.45 mg/ml of NaCl, 1.29 mg/ml of KCl 160 and 0.32 mg/ml of CaCl<sub>2</sub>·2H<sub>2</sub>O and pH adjusted at 6.5. SNF supplemented with mucin type III (1% sialic 161 acid content) at 0.1% was also used for the study. For further studies in dendritic cell culture, the stability 162 of the nanosystems was assessed in cell culture RPMI-1640 medium, following the change in particle size, 163 mean count rate and PDI over a period of 24 h. In brief, 20 µl of NCs were mixed with 980 µL of SNF with 164 0.1% mucin or 980 µl of RPMI, while nanoparticles suspended in SNF and water at same concentrations 165 are used as controls. The NCs in the different media were shaken at 100 rpm at 37°C using a constant-166 temperature shaker, at different time points (0, 6 and 24 h) the size and count rate of samples were measured 167 using DLS as described in Section 2.3.1.

## 168 2.4. Release studies

169 *In vitro* release studies of PsaA from the conjugated nanocapsules was performed by incubating non-170 conjugated CS-PsaA and conjugated CS-maleimide PsaA nanocapsules in a final volume of 1 mL of SNF 171 in a shaking incubator (Biosan Termo-Shaker TS-100C, 600 rpm at 37°C). At different time intervals (1, 172 3, 5, 8, 12 and 24 h), samples were centrifuged (5 min at 10,000 g and RT) and 250  $\mu$ L of supernatant were 173 collected for analysis and replaced with fresh SNF medium to maintain sink conditions [22]. The amount 174 PsaA contained in the supernatant at scheduled time intervals were subsequently analyzed by absorbance 175 measurement in a multilabel plate reader using BCA assay at 562 nm.

## 176 2.5. Blood samples and dendritic cell preparation

Heparinized blood samples were obtained from healthy donors after informed consent. The *buffy coats*from anonymous donors were donated by the Organ and Blood Donation Agency (ADOS; Santiago de
Compostela. Spain). The peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll gradient
centrifugation method [23]. Briefly, blood was diluted with PBS (1:1) and layered onto Ficoll-Paque<sup>TM</sup>
PLUS at a ratio of 2:1 (blood:Ficoll). Different components were isolated after centrifugation (Allegra X12R, Beckman Coulter) at 400 g for 30 min at RT, and PBMCs were collected from the interface, washed

twice with PBS and centrifuged again (300 g, 10 min at RT). Cells were resuspended in  $R_2$  medium (RPMI-184 1640 supplemented with 2% heat-inactivated FBS and 1% of PSG). The density was adjusted to  $1\times10^6$ 185 cells/mL and 10 mL of cells were seeded into 75 cm<sup>2</sup> cell culture flask for 2 h (37°C, 5% CO<sub>2</sub>). After the 186 incubation period, non-adherent cells (peripheral blood lymphocytes or PBLs) were washed with PBS and 187 attached monocytes were cultured for another 6 days, renewing half of the medium after three days, in R10 188 medium (RPMI-1640 supplemented with 1% antibiotics and 10% FBS) in the presence of IL-4 and GM-189 CSF (both at 100 ng/mL) to allow the cells to differentiate into DCs [24][25].

- 190 2.6. NCs toxicity on immune cells
- **191** 2.6.1. MTS assay

192 The cytocompatibility of the antigen loaded CS-maleimide PsaA NCs with the dendritic cells was studied 193 using MTS assay, and the presence of the soluble formazan product was determined by measuring the 194 absorbance that is directly proportional to the number of viable cells [26]. Monocyte differentiated 195 immature DCs (iDCs) were added into 48-well microplate  $(1 \times 10^6 \text{ cells/mL})$  and blank CS-maleimide and 196 CS-maleimide PsaA NCs with a concentration range from 400 µg/ml to 25 µg/ml were incorporated. As a 197 negative control (0% toxicity), iDCs in culture medium was used, whereas, for the positive control (100% 198 toxicity), iDCs were incubated with Triton X-100 (0.5%). In the same manner, macrophage Raw 264.7 199 cells were incubated with blank CS-maleimide and CS-maleimide PsaA NCs and treated using the same 200 procedure as iDCs. After 4 and 24 h of incubation under standard sterile conditions for cell culture (37°C 201 and 5% CO<sub>2</sub>), cells were collected and centrifuged (Microfuge 5427-R, Eppendorf, 500 g, 5 min at RT) for 202 the removal of un interacted nanocapsules. Finally, the cells were incubated with 10 µL of MTS reagent 203 and the absorbance was measured at 490 nm using a microplate reader.

204 2.6.2. 7-AAD assay

Cytotoxicity studies on the dendritic cells were also carried out using the intercalative DNA fluorescent
dye 7-AAD. iDCs were incubated for 24 h with different CS-maleimide PsaA NCs concentrations from
900 µg/mL to 50 µg/mL and after the incubation period, cells were washed and stained with 0.05 µg/µL of
7-ADD (30 min at 4°C) for analysis by flow cytometry (BD FACSCalibur<sup>™</sup>, Becton Dickinson). The
emission of 7-AAD was detected in the FL-3 channel at 650 nm. The analysis was performed with Flowing
software (Cell Imaging Core, Turku Biotechnology Center, Turku, Finland) [27].

#### 211 2.7. Interaction of NCs with immune cells

212 The analysis of the uptake of CS-maleimide PsaA NCs by the DCs and Raw 264.7 cells was processed by 213 means of confocal laser scanning microscopy (CLSM) and FESEM microscopy, respectively. For CLSM, 214 DCs were incubated with Cy5-labeled nanosystems at a concentration of 150 µg/ml and they were 215 visualized by confocal microscopy (Leica SP5, Mannheim, Germany) after 24 h. For FESEM analysis, Raw 216 264.7 cells were seeded on a poly-L-Lysine coated cellware (Corning Life Sciences, MA, USA) and 217 nanocapsules were added, and allowed to incubate for 24 h. Later, the cells were fixed using 4% 218 paraformaldehyde (PFA), washed and gradually dehydrated using increasing ethanol concentrations (30%, 219 70%, 96%, 100%). Cells were placed in the desiccator overnight and were sputter coated with iridium 220 before visualization [26].

### 221 2.8. Human DCs phenotype analysis

iDCs were incubated with the conjugated CS-maleimide PsaA NCs at a final concentration of 150 µg/ml
during 48 h. Cells were washed twice (400g, 6 min at RT) to eliminate excess NCs, resuspended in PBS
and stained with optimal amounts of different antibodies (CD1a-FITC, CD83-APC and CD86-PE) for 25
min at RT, in the dark. Finally, levels of maturation markers were quantified by flow cytometry.

## 226 2.9. NCs tolerogenic effect in immature DCs

227 2,3-Indoleamine dioxygenase (IDO) expression was evaluated in iDCs maturation after conjugated CS-228 maleimide PsaA NCs exposition. In brief,  $1.25 \mu l$  of L-tryptophan (100  $\mu$ M) was added to the iDCs medium 229 during the last 4 h of incubation. Then, cells were centrifuged (1,000 g, 5 min at RT) and supernatants were 230 mixed with 30% trifluoroacetic acid (2:1 v/v) and centrifuged again (10,000 g, 5 min, RT). The supernatant 231 was mixed with the Ehrlich Reagent (1:1 v/v) and absorbance at 490 nm was determined using a microplate 232 reader as indicated.

## 233 2.10. Activation of CD4 and CD8 T cells by NCs

After total monocyte differentiation into iDCs, they were harvested, resuspended in R10 medium and iDCs (1x10<sup>6</sup> cells/mL) were co-incubated with 150 µg/ml of blank CS-maleimide NCs, CS-maleimide PsaA NCs and PsaA. As a negative control (no activation), iDCs in culture medium were used, whereas for the positive control (total activation), mature DCs (mDCs) were obtained by incubation of iDCs with bacterial LPS (20 ng/ml) and IFN- $\gamma$  (200 IU/ml). After 48 h, cells were harvested and centrifuged to remove nanocapsules (300 g, 10 min at RT). In parallel, allogenic PBLs were obtained from *buffy coats* after 2 h of PBMCs incubation with R2 medium and they were co-incubated with DCs for 12 days, renewing culture media and splitting the cells as necessary (usually every 2-3 days). Non-adherent cells were collected and centrifuged (500 g for 5 min at RT), washed and divided into two different groups. CD4-APCs together with CD25-PE (5  $\mu$ L/each) were added to the first, while CD8-APCs together with CD28-PE (5  $\mu$ L/each) were added to the latter and left to incubate at 4°C for 25 min in darkness. After incubation, cells were washed and centrifuged (400 g for 6 min at RT) for their analysis by flow cytometry as described above.

#### 246 2.11. Cytokine secretion by PBMCs incubated with different NCs

247 PBMCs (1x10<sup>6</sup> cells/mL) were collected from healthy donors and incubated with blank CS-maleimide NCs, 248 CS-maleimide PsaA NCs and PsaA alone (150 µg/mL) (5% CO<sub>2</sub>, 37 °C) for 2 h. After that, cells were 249 washed and centrifuged (300 g for 10 min at RT), thus removing the nanocapsules. Then, BFA (10 mg/ml, 250  $5 \,\mu$ L/well) was added to block the secretion of cytokines and kept for overnight incubation. The following 251 day, cells were centrifuged again under the same conditions, the PBMCs surface was stained with CD3-252 FITC (10  $\mu$ L/well) antibody and left for 15 min at 4°C in darkness. Cells were washed, centrifuged (400 g, 253 6 min at RT) and fixed with 1% PFA under constant agitation to avoid cell aggregation, and were incubated 254 again for 15 min in darkness. Cell membrane was permeabilized with 1% saponin and centrifuged again 255 under the initial conditions for an intercellular staining with TNF $\alpha$ -PE cytokine antibody (5  $\mu$ L/well) and 256 incubated for 15 min at 4°C in darkness. Finally, cells were washed twice with 0.1% saponin buffer and 257 fluorescence signals were measured by flow cytometry as indicated.

## 258 2.12. Statistical analysis

Results were expressed as mean ± standard deviation (SD) and mean ± standard error mean (SEM) for
dendritic cells studies. Data analyses were carried out using GraphPad Prism v.6.01 software (GraphPad

261 Software Inc., San Diego, CA, USA). Statistical analyses using the 2-way ANOVA test in combination

with Dunnett's multiple comparisons test were used to determine the difference between donor groups.

## 263 **3. Results and discussion**

#### 264 3.1. Functionalization of the polymer and protein and their characterization


#### 265 3.1.1. <u>PsaA-SATA conjugation</u>

266 In the search for a serotype-independent pneumococcal vaccine, the use of highly conserved pneumococcal

- 267 protein antigens has become an attractive alternative to achieve immune response against S. pneumoniae
- 268 [28]. PsaA, a 35-kDa lipoprotein present in all serotypes known to date, is capable of inducing herd

immunity against the pathogen [29], and studies of its co-administration with PCV7 have demonstrated toincrease serotype coverage and immunogenicity of PCV7 by reducing nasopharyngeal carriage [30].

271 In our study, the PsaA was obtained by rDNA technology and subsequently, the free amines present in the 272 lysine amino acids of the PsaA were derivatized to produce a thiolated protein. The functionalization with 273 SATA adds sulfhydryl groups to proteins in a protected form. Thus, PsaA when modified with SATA can 274 be stored for extended time periods and the sulfhydryl groups required for the conjugation reactions will be 275 exposed by treating with the hydroxylamine. Conjugation reaction between the PsaA protein and the SATA 276 group is described in Supplementary Figure 1a. The MALDI-TOF technique (Figure 1a) used to 277 determine the protein molecular weight showed that the purified PsaA had a mass of 34,059 Da, while 278 PsaA-SATA conjugated protein had a mass of 35,683 Da. The difference in the molecular weight between 279 PsaA and PsaA-SATA confirms the successful conjugation of SATA to PsaA antigen in the ratio of 13:1. 280 The presence of multiple sulfhydryl groups on the protein helps its efficient coupling to the nanocapsules. 281 Similarly, Derksen et al., have described the use of protein functionalized with SATA for its surface 282 conjugation to liposomes containing maleimide residues [31]. In addition to this, the sulfhydryl modified 283 proteins were also used to prepare protein-protein conjugate nanoparticles to enhance the immunogenicity 284 of the protein antigens [32]. The conformation of the protein antigen is pivotal in conserving the potential 285 epitopes that are responsible for the immunogenicity [33]. The CD spectra (Figure 1b) revealed no changes 286 in the secondary structural conformation of the PsaA-SATA compared to the existing literature [19]. The 287 PsaA antigen presented negative peaks at 208 and 221 nm, which were also observed in the conjugated 288 PsaA-SATA antigen, indicating a similar protein folding pattern of alpha helixes and beta sheets in both 289 cases [19,34].



290


Fig. 1: Pre-formulation characterization of PsaA and its conjugate PsaA-SATA: (a) graphs of MALDITOF for PsaA (blue line) and PsaA-SATA conjugate (green line). (b) Overlay of CD spectra for PsaA and
PsaA-SATA conjugate.

## 294

#### 3.1.2. Chitosan-maleimide conjugation

295 Chitosan is an attractive biomaterial with amine groups for conjugation of ligands [35], and previous studies 296 have reported its successful covalent conjugation with maleimide groups [36]. Maleimide selectivity and 297 efficient cross-linking with thiol groups, via Michael addition, has allowed the bioconjugation of chitosan 298 with biomolecules such as peptides [37] or nucleic acids [38], avoiding the generation of reaction by-299 products. In the present work, conjugation between CS and maleimide propionic acid was performed and 300 CS and conjugated CS-maleimide samples were freeze-dried and redispersed in deuterium oxide (D<sub>2</sub>O). 301 Conjugation reaction between the polysaccharide and the 3-maleimidopropionic acid group is described in 302 Supplementary Figure 1b. Their H<sup>1</sup>-NMR spectra had been recorded from 0 to about 10 ppm using a 303 proton NMR spectrometer, to confirm the successful conjugation. The typical CS spectrum was confirmed in Figure 2b, which presented a signal at  $\delta \sim 4.9$ , corresponding to H<sub>7</sub> anomeric proton, the ring proton 304 305 chemical shift (H<sub>2</sub>-H<sub>6</sub>) as overlapping signals at  $\delta \sim 3.6$ -4.0, which confirmed the presence of the

306 glucosamide moiety, while adjacent amino group ring proton (H<sub>1</sub>) appeared at  $\delta \sim 3.2$ . The methyl group 307 of the non-deacetylated part of the polysaccharide was expressed at  $\delta \sim 2.1$  (NHCOCH<sub>3</sub>), [39], and 308 deacetylation degree >85% could also be confirmed basis of proton integrals. In Figure 2a there still 309 appeared signals similar to that native chitosan signals at 2.1 ppm (NHCOCH<sub>3</sub>), anomeric proton at 2.9 ppm 310 (H<sub>1</sub>) and glucosamide moiety at 3.8-4 ppm (H<sub>2</sub> to H<sub>6</sub>) [40]. The presence of new peaks Hb and Hc at ~ 3.5 311 and 2.7 ppm, respectively, representative of typical protons of the maleimide moiety (Figure 2c), were in 312 accordance with the chitosan chemical modification, proving the successful attachment of chitosan to 313 maleimide propionic acid.




**Fig. 2**: H<sup>1</sup>-NMR (400 MHz, D<sub>2</sub>O) spectra and integration peaks of Chitosan-maleimide (**a**), Chitosan (**b**), 3-maleimidopropionic acid (**c**), and their respective chemical structures (right). All chemical shifts were expressed as  $\delta$  in parts per million (ppm), using the chemical shift of the residual solvent resonances as references (D<sub>2</sub>O:  $\delta$  = 4.80 ppm).

## 319 3.2. Preparation and physicochemical characterization of chitosan nanocapsules

**320** 3.2.1. Physicochemical characterization of nanocapsules

The combination of antigens with adjuvants into an optimal delivery system is a key for the development of a successful vaccine. In addition, aspects such as particle size or surface charge are crucial for the interaction and uptake of particles by immune cells [41]. The delivery carrier was selected based on the knowledge generated by our group and the protein antigen PsaA was associated on the surface of the nanocapsule to obtain a nanovaccine that mimics the pathogen structure and be able to generate a specific immune response.

327 CS NCs are made of a hydrophobic oily core surrounded by a hydrophilic coating. This core-corona 328 structure uses lipids as core components allowing nanocapsules to interact with and penetrate through 329 mucosal surfaces [42]. During the first step, we evaluated different ratios of surfactant:oil (data not shown) 330 and the impact on the particle size and polydispersity of the resulting nanoemulsion (NE), and we selected 331 nanometric size particles with narrow size distribution to form the oily core of the nanocapsules. The 332 amount of Miglyol<sup>®</sup> was the main variable affecting the size of nanocapsules. Similar results were 333 previously observed for other polymeric nanocapsule compositions such as those described by González-334 Aramundiz et al [21]. The use of non-ionic surfactants such as PEG-st 40 helps in preventing aggregation 335 of particles during the formation of initial NE [43], whilst SGC was used as a co-surfactant that provides 336 negative charge and enhanced stability to the oil core of the NCs [44]. As shown in Figure 3, chitosan 337 molecules were anchored to the surface due to ionic interactions between polymer chains and negatively 338 charged oily core, following an ionic interaction procedure, as previously described for chitosan coating 339 colloidal systems [45], resulting in a core-coated nanostructure.



340

Fig. 3: Schematic representation of chitosan polymeric NCs developed in this work. Non-conjugated CS antigen nanocapsules (left) and CS-antigen nanocapsules after thiol/maleimide conjugation (right). Design
 was created by Biorender<sup>®</sup> and ChemDraw<sup>®</sup> graphics programs.

344 NCs were prepared using the solvent displacement technique. As shown in Table 1, in all cases, they were 345 monodisperse with a size range of 245-266 nm and the presence of a CS coating surrounding the oily core 346 was corroborated by obtaining a positive surface charge of +30 mV, due to the amine groups in the CS 347 structure. The NCs exhibited an increase in particle size and the surface charge decreased in the presence 348 of antigen when compared with blank CS NCs. This increase in size could be considered as an indicator of 349 a successful binding between the protein and the surface CS of the nanocapsules, and it could also be related 350 to the presence of maleimide-groups as previously described for the development of thiolated-CS liposomes [46]. 351

## 352 3.2.2. <u>Association efficiency</u>

Nanoparticle formulations prepared with thiol-maleimide coupling resulted in higher PsaA association efficiency than formulations without this covalent modification. Namely, the association efficiency of protein conjugated to the surface of NCs was approximately 3 times higher with PsaA-SATA compared to ones where the antigen was associated without polymer-protein conjugation reaction (86% versus 34%, approximately). Covalently conjugated NCs also preserved their particle integrity and physicochemical properties, so that they were expected to improve antigen delivery and activation of APCs, enhancing immunogenicity compared to non-conjugated NCs.

For uptake studies, the conjugation of CS-maleimide with Cy5 dye was first performed and nanocapsules
were prepared using the same procedure previously described. The incorporation of the fluorophore did not
alter the NCs original properties.

Formulation name	Size (nm)	Antigen:CS ratio	PDI	Z potential (mV)	Association Efficiency (%)
CS NCs	$245\pm20$	-	< 0.1	$31\pm2$	-
CS PsaA NCs	$248\pm21$	1:5	< 0.1	$29\pm2$	$34\pm9$
CS-maleimide NCs	252 ± 23	-	< 0.1	31 ± 1	-
CS-maleimide PsaA NCs	266 ± 32	1:5	< 0.2	30 ± 1	86 ± 13
CS-maleimide Cy5 PsaA NCs	254 ± 16	1:5	< 0.1	29 ± 1	-

363

Table 1: Physicochemical characterization and association efficiency of antigen-conjugated and non conjugated NCs. Particle size and polydispersity index were obtained by Dynamic Light Scattering. Data
 represent mean ± S.D., n=8. CS: Chitosan; NCs: Nanocapsules; PDI: Polydispersity index.

The NTA analysis (**Figure 4a**) of conjugated CS-maleimide PsaA NCs also confirmed previously reported DLS data showing a particle population of 268 ± 98.5 nm (red line), which corresponds to NCs. Analysis of the conjugated CS NCs in solution showed that the concentration/size distribution was less homogeneous than in case of lyophilized NCs, with more than one population of particles. Smaller NCs could be derived of NTA technique, where a higher dilution of CS-maleimide NCs (1:100) might had occasioned their rupture [47], while aggregation of primary NCs into large NCs could be consequence of the decrease of repulsive forces between the particle surfaces after chemical coating modification [48].

374 To assess the stability of conjugated CS-maleimide PsaA NCs after freeze drying process, formulations 375 were lyophilized in the presence of trehalose 5%. After this procedure, the nanocapsules (purple line) were 376 easily redispersed in ultrapure water and a slight change (< 50 nm) in the particle diameter was observed 377 after NTA analysis. It was also observed that a lower concentration of nanocapsules tended to aggregate 378 after lyophilization procedure compared with NCs in solution, which confirmed trehalose as an appropriate 379 cryoprotectant to prevent nanoparticle aggregation. Production yield calculated by the difference obtained 380 between the initial weight and the weight obtained after lyophilization was 67±21%. This freeze-dried 381 chitosan nanocarrier could preserve their integrity upon storage without compromising its physicochemical 382 properties, which is a very attractive feature in terms of developing a future thermostable vaccine 383 formulation [49].

#### 384 3.2.3. <u>Morphological characterization</u>

Different microscopic techniques were used to characterize the conjugated NCs. FESEM and STEM microscopy images revealed a homogeneous population of particles with round-shape structures, which confirm the spherical structure of the NCs. The average particle physical diameter was around 220 nm that corroborated the hydrodynamic NCs diameter values obtained by DLS, where slightly higher values were influenced by the interactions between the particles and the dispersion media (**Fig. 4b and 4c**) [50].




Figure 4: (a) Representative image of the particles size distribution by Nanoparticle Tracking Analysis of conjugated nanocapsules in solution (red line) and conjugated nanocapsules resuspended after lyophilization procedure (purple line), with the mean particle size ± standard deviation. Electron microscopy scanning (b) and transmission (c) images of conjugated Chitosan-maleimide PsaA NCs. Scale bars are indicated in each image. NCs: Nanocapsules.

## 396 3.2.4. <u>Colloidal stability</u>

397 Apart from obtaining adequate physicochemical properties, particle stability must be guaranteed for the 398 developed nanosystems. The understanding of the colloidal stability and aggregation of the nanosystems in 399 the biological media is important for their rational design. Moreover, the nanoparticle aggregation has 400 shown to influence the *in vitro* cellular responses. Our studies showed that the size of the CS-maleimide 401 PsaA NCs remained unchanged and no signs of aggregation were observed during a period of 24 h in both 402 RPMI-1640 and SNF in suspension (Figure 5a), and after the freeze-drying process (Figure 5b), which 403 suggest that the NCs were stable in the biological media and could be further proceeded for primary cell 404 culture studies. However, there was a considerable increase in particle size when SNF medium was 405 supplemented with mucin type III. This increase in the particle size of the NCs can be attributed to the 406 decrease in the Brownian motion of the particles due to higher viscosity of the medium in the presence of 407 mucin, as well as structural properties of CS such as deacetylation degree or molecular weight [51]. This 408 electrostatic interaction between the positively charged chitosan nanocapsules and the negatively charged 409 mucin molecules yields protein-polysaccharide complexes [52]. According to Feng et al [53], dynamic 410 viscosity could be calculated by DLS method, using water viscosity values (~0.89 cP at 25°C) and 411 commercial polystyrene latex nanoparticles of known size (Magsphere Inc, USA) as reference. Values of 412 ~1.21 cP for SNF media and ~1.41 cP for SNF media supplemented with mucin type III confirmed this 413 increase in dynamic viscosity. Conjugated CS-maleimide PsaA NCs became larger and their brownian 414 movement slower after incubation in SNF with mucin Type III, which might reflect the mucoadhesive 415 properties of chitosan nanocapsules with mucin macromolecules [54]. Chitosan-mucin interaction by 416 hydrogen and electrostatic bonding has been shown to be suitable for pharmaceutical and biomedical 417 applications in the oral, nasal or ocular routes [55]. However, future in vivo experiments will be needed to 418 confirm the mucoadhesive properties of CS-PsaA nanocapsules conjugated for nasal application. In 419 addition, all formulations have maintained constant stability profiles in aqueous suspension at 4 °C for at 420 least, 1 month (Supplementary Figure 2).







Fig. 5: Stability of conjugated CS-maleimide PsaA NCs in suspension (a) and lyophilized (b) conditions
in water, cellular media (RPMI), simulated nasal fluid alone (SNF) and with mucine type III (SNF+ 0.1%
Mucin). Bars represent size (nm), and dots represent derived count rate (kcps) (mean± SD; n=3).

## 425 3.3. Release studies

426 The in vitro release behavior of PsaA from CS NCs was investigated using simulated nasal fluid (SNF pH 427 = 6.5). The accumulative release study of non-conjugated CS-PsaA and conjugated CS-maleimide PsaA 428 NCs was carried out after 24 h of nanocapsules incubation in SNF by analyzing the total amount of free 429 protein in the media at each time point. Total loading was estimated considering the previously reported 430 association efficiency rates achieved after physical (CS-PsaA NCs) and chemical (CS-maleimide PsaA 431 NCs) conjugation. Values of protein released over time were obtained by extrapolation with a BSA protein 432 concentration range in SNF. As observed in Figure 6, NCs presented an initial fast release during the first 433 3 hours of approximately the half of the PsaA antigen from the formulations to the medium. The release 434 experiment indicated that the protein was gradually released from the nanocapsules in a time-dependent 435 manner, and that this antigen release remained stable after 8 h. However, a sustained antigen release pattern 436 was observed after 3 hours in the CS-PsaA NCs, reaching values of 100% of the release at 24 h, contrary 437 to the CS-maleimide NCs, where the release was slowed down, reaching values over 76% at 24 h. The 438 relatively slower and sustained release in conjugated CS-maleimide PsaA formulation may be ascribed to 439 the chemical conjugation which produced a stronger interaction between the antigen and the 440 polysaccharide. As showed in similar studies in maleimide-bearing nanogels [56] and maleimide-441 functionalized PEGylated liposomes [57], carrier capacity to retain and release the drug was sustained for 442 a prolonged time-period. Overall, both conjugated and free antigen release presented a biphasic profile with 443 a faster initial release followed by a second phase with slow and delayed tendency release profile.




444

Fig. 6: *In vitro* cumulative release profile of PsaA antigen from chitosan PsaA and chitosan–maleimide
PsaA NCs (mean± S.D.; n=6). CS: Chitosan, NCs: Nanocapsules.

## 447 3.4. NCs toxicity on immune cells

448 To investigate the biocompatibility of both types of conjugated CS-maleimide nanocapsules (blank and 449 antigen loaded), an in vitro MTS assay was performed to study the influence of the nanocapsules on the 450 metabolic activity of macrophages and DCs. Since cationic nanoparticles generally have better electrostatic 451 attractions with the negatively charged cell surface, their toxicity also might increase [58]. After 4 h (Figure 452 7a) and 24 h (Figure 7b) of CS-maleimide and CS-maleimide PsaA NCs incubation with macrophage Raw 453 264.7 cells, MTS assay showed a significant reduction in cell viability (mitochondrial reductase activity) 454 at concentrations > 200  $\mu$ g/mL. Membrane damage was more pronounced in blank CS-maleimide NCs, 455 being practically total at values of 800 µg/mL, while in the case of protein-conjugated nanocapsules it 456 remained around 40% at higher doses. Similar effects on toxicity were observed after incubation of NCs with iDCs for 24 h (Figure 7c), although in this case, toxicity was apparently higher in blank CS-maleimide
NCs.

In a second instance, cell toxicity values were also verified *via* 7-AAD cytotoxicity assay test at 24 h.
Considering that dendritic cells with compromised membranes were stained with 7-AAD, untreated cells
were use as control for viable cells. The flow cytometry analyses performed (Supplementary Figure 3)
showed a decrease in the number of viable cells as the CS-maleimide PsaA NCs concentration increased,
reaching dendritic cell viability values of 65% at NCs concentrations of 900 µg/mL.



464


Fig. 7: Effect of CS-maleimide and CS-maleimide PsaA NCs on the viability of Raw 264.7 macrophages
(a, b) and immature dendritic cells (c). MTS assay performed on Raw 264.7 cell lines incubated with either
CS-maleimide (blue lines) or CS-maleimide PsaA (red lines) NCs using different concentrations of
nanocapsules during (a) 4 h and (b) 24 h. (c) MTS assay performed on iDCs after incubating them with
different concentrations of nanocapsules for 24 h. Results were normalized with the percentage of live iDCs
incubated in culture media alone and dead iDCs incubated with Triton (5%, 1x) (mean ± S.D; n=4). CS:
Chitosan; NCs: Nanocapsules.

#### 472 3.5. Interaction of NCs with immune cells

473 Immune cells are able to capture antigens in many different ways, such as phagocytosis, macropinocytosis,
474 or by expressing surface receptors causing endocytosis [59]. Once the antigen has been captured by the
475 antigen presenting cells, it is processed and presented on the cell surface by Major Histocompatibility

476 Complex (MHC) [60]. To confirm whether our nanocarriers were able to interact with such immune cells, 477 we examined the efficacy of CS-maleimide PsaA NCs on antigen uptake in primary cultures of human 478 monocyte-derived iDCs and in the macrophage Raw 264.7 cell line. After incubating the Cy5-labelled NCs 479 (both blank and antigen loaded), the presence of intracellular fluorescence due to the Cy5-labelled NCs 480 confirmed the internalization of the nanocapsules by the DCs. The images obtained from the confocal 481 scanning microscopy confirmed that the nanocapsules (top Figure 8a, red channel) were located within the 482 dendritic cells (bottom, contrast microscope DiC channel) and intracellular distribution of CS-maleimide 483 NCs could be seen throughout the different sections of dendritic cells (also see online video resource in 484 Supplementary material). The physical appearance of DCs could also provide information about their 485 maturation and activation status, for example, by the formation of their characteristic dendrites as seen in 486 our case [25].

On the other hand, the interaction of macrophages with nanocapsules was analyzed by FESEM microscopy.
The presence of protrusions on the surface of cells observed in FESEM images (Figure 8c) suggested a
possible grouping of nanocapsules and recognition by macrophages.




490

491 Fig. 8: CLSM images of Cy5-labelled CS-maleimide PsaA NCs incubated with DCs (a) and FESEM
492 images of Raw 264.7 cells alone (b) and after incubation with CS-maleimide PsaA NCs (c). Raw 264.7
493 cells (blue), and nanocapsules (purple, indicated with white arrows) in (b) and (c) were artificially colored
494 to ease their visualization.

496 To evaluate the effect that NCs may have on iDC phenotype, the expression of T lymphocyte costimulatory 497 molecules CD83 and CD86 (indicators of pro-inflammatory activated phenotype in dendritic cells) were 498 analyzed by flow cytometry. The co-stimulatory marker CD86 designates to be a marker primary DCs 499 maturation expressed within first 24 h and interacts with the CD28 for the T cell activation, while the 500 increased CD83 is observed in mature/activated DCs. Several studies have proven that antigen delivery to 501 DCs upregulates expression of both CD83 and CD86 that are known to induce T cell receptor signalling 502 and promote T cell activation [61]. In our study, both the blank and antigen loaded CS-maleimide NCs 503 showed an increase in the expression of these maturation markers. The expression of CD83 and CD86 504 (Figure 9a) were 4 folds higher in the case of DCs primed with blank and antigen loaded CS-maleimide 505 NCs when compared to iDCs (MFI=1). However, iDCs treated with PsaA alone displayed a 2 and 3-fold 506 lower expression of CD83 and CD86 markers, respectively. Overall, the results suggest that either the blank 507 or antigen loaded NCs can upregulate the co-stimulatory markers in comparison to the antigen alone.

## 508 3.7. NCs tolerogenic effect on immature DCs

509 Antigen-presenting cells such as iDCs play an important role in immune regulation, not only as inductors 510 but also inhibitors of an immune response. 2,3-Indoleamine dioxygenase (IDO) is an enzyme involved in 511 tryptophan catabolism, essential for the growth of microorganisms, which regulates T-cell tolerance [62]. 512 IDO is a potent immune-suppressive enzyme in macrophages and dendritic cells whose physiological 513 function is to catabolize the essential amino acid tryptophan into the stable metabolite, kynurenine which 514 is known to induce the apoptosis of Th1 cells in vitro [63]. In addition, it is known that the IDO expression 515 by the DCs can greatly impact peripheral tolerance and immune regulation. In this line, we performed a 516 study to evaluate if the NCs formulations were inducing a tolerogenic phenotype on iDCs in terms of T-517 cell suppression and tolerance promotion (opposite to a pro-inflammatory response), by quantifying the 518 IDO enzymatic activity after iDCs treatment with NCs. The results obtained from our study showed that 519 the response in the DCs treated with either blank or antigen loaded CS-maleimide NCs signal was similar 520 to one observed in iDCs (Figure 9b), indicating no tolerogenic effect of the NCs.



521

522 Fig. 9: (a) Quantification (%) of the expression of iDC maturation markers CD83 and CD86. Results are 523 expressed as the ratio between the markers mean fluorescence intensity (MFI) in iDCs incubated with the 524 different NCs and the MFI of iDC incubated in culture media alone (MFI=1). The dotted line corresponds 525 to the signal from the iDCs. (b) Indoleamine 2,3-dioxygenase (IDO) activity in dendritic cell cultures. iDCs: 526 immature dendritic cells; CS: Chitosan; NCs: Nanocapsules) (mean ± SEM; n=3 donors).

#### 527

## 3.8. Activation CD4 and CD8 T cells by NCs

528 Stimulation of antigen specific CD4+ and CD8+ T lymphocytes is essential for efficient adaptive immunity. 529 Therefore, we have assessed the ability of the DCs pulsed with antigen, blank CS-maleimide NCs or CS-530 maleimide PsaA NCs to activate T lymphocytes. The effect of conjugated NCs on the activation of T 531 lymphocytes in an allogenic response was analyzed by flow cytometry. Blank CS-maleimide, CS-532 maleimide PsaA NCs (150 µg/mL) and PsaA antigen alone were incubated with iDCs and then, the 533 capability of this NC-incubated iDCs to activate allogenic lymphocytes was analyzed quantifying the 534 expression levels of CD25 (for CD4 T lymphocytes) and CD28 (for CD8 T lymphocytes). As shown in 535 Figure 10, mature DCs (mDCs) showed a greater capacity of activating both CD4 and CD8 T lymphocytes 536 (black dots) than iDCs (open dots). On the other hand, preincubation of the iDCs with PsaA protein (green 537 dots), blank CS-maleimide NCs (blue dots), and CS-maleimide PsaA NCs (red dots), induced similar 538 percentages of activated CD4 and CD8 T lymphocytes when compared to iDCs.

539 In all cases, incubation of iDCs in the presence of NCs caused these APCs to have a similar capacity to 540 stimulate CD4 and CD8 lymphocytes to iDCs, and were lower compared to mDCs. Also, levels of both 541 activated CD4+CD25+ and CD8+CD28+ CD4 T cells were similar for loaded and non-loaded 542 nanocapsules. However, no significant differences were found between treatments, probably due to donor 543 variability. The similar values between both treatments on the effect of T cell activation could be a 544 consequence of the composition of the nanocapsules, rather than the presence of the antigen on the surface. 545 [64].





Fig. 10: Percentages (%) of activated T cells after iDCs incubation with formulations. Non-treated iDCs
and LPS and IFNy treated iDCs (mDCs) were used as controls (mean ± SEM; n=3 donors, 2-way ANOVA
test). CS: Chitosan; iDCs: immature Dendritic Cells; mDCs: mature Dendritic Cells; NCs: Nanocapsules.

## 550 3.9. Cytokine secretion by PBMCs incubated with different NCs.

546

551 In the process of developing a powerful immune response, dendritic cells capture antigens thanks to pattern 552 recognition receptors (PRRs), leading to phenotypic and maturation changes [65]. Depending on the 553 alterations they undergo and the co-stimulation molecules they express, different responses will take place 554 from the T cells (Th1, Th2 or Th17) [66]. The secretion of cytokines by Th1 CD4+ cells (such as IL-2, 555 IFNy, IL-10 or TNF $\alpha$ ) is necessary in order to achieve protection against pneumococcal infection [2]. 556  $TNF\alpha$ , secreted by either macrophages, monocytes or activated lymphocytes acts as an inflammatory 557 marker and protects against the infectious pathogens.  $TNF\alpha$  production can activate the T cells or can be a 558 product of the activated T cells. In this procedure, we quantified by intracellular cytokine staining the 559 production of TNFa by T lymphocytes (CD3+) and non-T cells (CD3-) after incubation with NCs. As can 560 be seen in **Figure 11**,  $TNF\alpha$  production was higher in the CD3- (monocytes) population, being around 5-561 8% compared to CD3+ (lymphocytes) population, where it did not exceed a 5% in any case. In both cases, 562 a higher percentage of  $TNF\alpha$ -positive cells was seen after incubated with the different NCs and the PsaA 563 protein compared to iDCs, especially for the CD3+ T cells. Although no statistical differences were found 564 in the different treatments due to the high variability among donors, the obtention of slightly higher cytokine 565 secretion levels in CS-maleimide PsaA NCs could be a consequence of the presence of PsaA attached on 566 their surface. These results were in agreement with previous studies evaluating the effect of cationic CS 567 NCs in inducing inflammatory responses, where cytokine levels were remarkable in one out of three donors 568 tested [67]. Likewise, when the PsaA protein was used, a clear increase in the percentage of TNF $\alpha$ -positive 569 cells was observed when compared to control cultures. This may indicate the external presence of the






Fig. 11: Percentages (%) of TNFα positive cells (CD3+ and CD3-) after treatment with CS-maleimide NCs,
antigen loaded CS-maleimide PsaA NCs and PsaA antigen alone (mean ± SEM; n=3 donors, 2-way
ANOVA test). CS: Chitosan; NCs: Nanocapsules.

#### 575 **4.** Conclusion

571

576 In the design of targeted nanovaccines towards nasal immune cells, a specific nanocarrier design with 577 mucoadhesive properties is crucial to achieve a higher residence time, avoiding mucociliary clearance and 578 crossing nasal epithelium. In this work, combination of the antigenic protein membrane PsaA together with 579 the high capacity of drug association of chitosan-maleimide modified nanocapsules has been positioned as 580 an interesting perspective for Streptococcus pneumoniae vaccination. Results supported the versatility of 581 non-capsular pneumococcal antigens as vaccine candidates for an efficient mucosal administration. 582 Developed nanocapsules presented a high effective payload of antigen after covalent thiol linkage, 583 mucoadhesiveness together with high physical and biological stability. The nanocapsules capacity to 584 interact with immune cells was conserved and enhanced compared to the free antigen, suggesting them a 585 "green light" future serotype-independent pneumococcal vaccine candidate. To further assess the ability of 586 these nanocapsules as vaccine delivery systems, the evaluation of antigen-specific responses and cytokine 587 profiles is currently under way.

#### 588 Acknowledgment & Funding

589 This work was supported by 'Ministerio de Economía y Competitividad' – (RETOS - SAF2016-79230-R 590 ERC2018-092841 and PID2019-108727RB-I00). Sandra Robla acknowledges the financial support from

26

591 the Xunta de Galicia (Centro Singular de Investigación de Galicia accreditation 2019-2022) and the 592 European Union (European Regional Development Fund - ERDF), code ED431G 2019/02. Maruthi 593 Prasanna acknowledges his doctoral fellowship from the European Commission, Education, Audiovisual 594 and Culture Executive Agency (EACEA), under the Erasmus Mundus program, "NanoFar: European 595 Doctorate in Nanomedicine and Pharmaceutical Innovation" (Project: 2015-01-C4). The authors have no 596 other relevant affiliations or financial involvement with any organization or entity with a financial interest 597 in or financial conflict with the subject matter or materials discussed in the manuscript apart from those 598 disclosed.

- 599 Conflicts of interest/Competing interests
- 600 Authors declare that they have no conflict of interest.

#### 601 Ethics approval

- 602 All procedures followed were in accordance with the ethical standards of the responsible institutional and
- 603 national committees on human experimentation and with the Declaration of Helsinki. Informed consent
- 604 was obtained from all patients for being included in the study.

#### 605 Consent to participate

- All institutional and national guidelines for the obtention and use of human blood were followed. Blood
- 607 was drawn with the informed consent of all subjects and appropriate permission was obtained from the
- 608 Institutional Ethics Committee (Comité Etico de Investigación Clínica de Galicia, CEIC).
- 609 No animal or human studies were carried out by the authors for this article.

#### 610 Consent for publication


- 611 Not applicable
- 612 Availability of data and material
- 613 Not applicable

#### 614 Code availability


- 615 Not applicable
- 616 Authors' contributions

617 Sandra Robla was in charge of the overall experimental execution, data analysis, writing and figure 618 preparation. Maruthi Prasanna contributed to the experimental execution and writing. Cyrille Grandjean 619 was involved in the synthesis and characterization of the PsaA antigen, reviewing and editing the 620 manuscript. R Varela-Calvino was involved in the design and supervision of the in vitro cell experiments, 621 reviewing and editing the manuscript. Noemi Csaba was involved in writing, reviewing, editing, 622 supervision, project design and administration.

#### 623 Supplementary material




Supplementary Figure 1: (a) Chemical conjugation scheme between PsaA and N-succinimidyl Sacetylthioacetate (SATA) group and (b) Chitosan and 3-maleimidopropionic acid group. Reaction synthesis
yield after purification and lyophilization procedure was ~ 30% and 50%, respectively.




628

629 Supplementary Figure 2: Stability of conjugated CS-maleimide PsaA NCs after 1 month under storage

630 conditions (dark and 4<sup>a</sup>C). Bars represent size (nm), and dots represent derived count rate (kcps) (mean±





633 Supplementary Figure 3: 7-AAD cytotoxicity study in function of the concentration of the conjugated CS-

- 634 maleimide PsaA NCs. (mean± SD; n=3). CS: Chitosan; NCs: Nanocapsules.
- 635 Online resource 1: Intracellular distribution of Cy5-labelled CS-maleimide PsaA NCs throughout the
- 636 different sections of DCs after confocal microscopy.

632

#### 637 **References**

- 638 1. Pérez-Dorado I, Galan-Bartual S, Hermoso JA. Pneumococcal surface proteins: When the whole is
- **639** greater than the sum of its parts. Mol Oral Microbiol. 2012;27:221–45.
- 640 2. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, et al. Prediction and
- 641 characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology.
- **642** 2014;141:514–30.
- 643 3. Mohammadzadeh M, Mamishi S, Pourakbari B, Mahmoudi S. Recent approaches in whole cell
- pneumococcal vaccine development : a review study. 2017;9:381–8.
- 4. Leites A, Paula A, Argondizzo C, Esteves S, Jessouron E, Galler R, et al. Cloning and optimization of
- 646 induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli
- and recombinant protein stability during long-term storage. Protein Expr Purif. Elsevier Inc.; 2011;78:38–
- **648** 47.
- 5. Bartual SG, Alcorlo M, Martínez-Caballero S, Molina R, Hermoso JA. Three-dimensional structures of
- Lipoproteins from Streptococcus pneumoniae and Staphylococcus aureus. Int J Med Microbiol. Elsevier;
  2017;1–13.
- 652 6. Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesin A
- **653** (PsaA): A review. Crit Rev Microbiol. 2008;34:163–73.
- 654 7. Zheng Z, Diaz-Arévalo D, Guan H, Zeng M. Noninvasive vaccination against infectious diseases. Hum
- 655 Vaccines Immunother. 2018;14:1717–33.
- 8. Almeida\* AJ, Florindo HF. Chapter 3.1. Nanocarriers Overcoming the Nasal Barriers: Physiological
- 657 Considerations and Mechanistic Issues. 2012. p. 117–32.
- 9. Calvo P, Remuñan-López C, Vila-Jato JL AM. Chitosan and chitosan/ethylene oxide-propylene oxide
- block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res.;
- 10. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev.
- 661 Elsevier B.V.; 2009;61:140–57.
- 11. Illum L. Nasal drug delivery Possibilities, problems and solutions. J Control Release. 2003;87:187–
  98.

- 12. Slütter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target. 2008;16:1–17.
- 13. Lewis KL, Reizis B. Dendritic cells: Arbiters of immunity and immunological tolerance. Cold Spring
  Harb Perspect Biol. 2012;4.
- 14. Cole J, Aberdein J, Jubrail J, Dockrell DH. The Role of Macrophages in the Innate Immune Response
- to Streptococcus pneumoniae and Staphylococcus aureus. Adv Microb Physiol. 1st ed. Elsevier Ltd.;
- 669 2014. p. 125–202.
- 670 15. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides.
- 671 Expert Opin Drug Deliv. 2005;2:843–54.
- 672 16. Prego C, Torres D, Alonso MJ. Chitosan nanocapsules: A new carrier for nasal peptide delivery. J
- **673** Drug Deliv Sci Technol. Elsevier Masson SAS; 2006;16:331–7.
- 674 17. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev.
- 675 Elsevier B.V.; 2010;62:3–11.
- 18. Shi GN, Zhang CN, Xu R, Niu JF, Song HJ, Zhang XY, et al. Enhanced antitumor immunity by
- 677 targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Biomaterials.
- 678 Elsevier Ltd; 2017;113:191–202.
- 19. Prasanna M, Soulard D, Camberlein E, Ruffier N, Lambert A, Trottein F, et al. Semisynthetic
- glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccine. Eur J Pharm Sci. Elsevier;
  2019;129:31–41.
- 682 20. Grenha A. Chitosan nanoparticles: A survey of preparation methods. J Drug Target. 2012;20:291–
  683 300.
- 684 21. González-Aramundiz JV, Presas E, Dalmau-Mena I, Martínez-Pulgarín S, Alonso C, Escribano JM, et
- al. Rational design of protamine nanocapsules as antigen delivery carriers. J Control Release. Elsevier
- 686 B.V.; 2017;245:62–9.
- 687 22. Shen J, Burgess DJ. In vitro dissolution testing strategies for nanoparticulate drug delivery systems:
  688 recent developments and challenges. Drug Deliv Transl Res. 2013;3:409–15.
- 689 23. Posch W, Lass-Flörl C, Wilflingseder D. Generation of human monocyte-derived dendritic cells from
- 690 whole blood. J Vis Exp. 2016;2016:2–7.

- 691 24. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y, et al. Immunobiology of Dendritic
- 692 Cells. Annu Rev Immunol. 2000;18:767–811.
- 693 25. Kowalewicz-Kulbat M, Ograczyk E, Krawczyk K, Rudnicka W, Fol M. Type of monocyte
- 694 immunomagnetic separation affects the morphology of monocyte-derived dendritic cells, as investigated
- by scanning electron microscopy. J Immunol Methods. Elsevier B.V.; 2016;439:79–82.
- 696 26. Hu X, Zheng W, Wang L, Wan N, Wang B, Li W, et al. The detailed analysis of the changes of
- 697 murine dendritic cells (DCs) induced by thymic peptide: Pidotimod(PTD). Hum Vaccines Immunother.
- **698** 2012;8:1250–8.
- 699 27. Lecoeur H, De Oliveira-Pinto LM, Gougeon ML. Multiparametric flow cytometric analysis of
- biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D
- 701 assay. J Immunol Methods. 2002;265:81–96.
- 702 28. Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccines
  703 Immunother. 2016;12:383–92.
- 704 29. Tai SS. Streptococcus pneumoniae protein vaccine candidates: Properties, activities and animal
- 705 studies. Crit Rev Microbiol. 2006;32:139–53.
- 30. Whaley MJ, Sampson JS, Johnson SE, Rajam G, Stinson-Parks A, Holder P, et al. Concomitant
- administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A
- 708 colonization in a murine model. Vaccine. Elsevier Ltd; 2010;28:3071–5.
- 31. Derksen JTP, Scherphof GL. An improved method for the covalent coupling of proteins to liposomes.
  BBA Biomembr. 1985;814:151–5.
- 711 32. Scaria P V., Chen B, Rowe CG, Jones DS, Barnafo E, Fischer ER, et al. Protein-protein conjugate
- nanoparticles for malaria antigen delivery and enhanced immunogenicity. PLoS One. 2017;12:1–19.
- 713 33. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, et al. Prediction and
- characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology.
- **715** 2014;141:514–30.
- 716 34. Couñago RM, Ween MP, Begg SL, Bajaj M, Zuegg J, O'Mara ML, et al. Imperfect coordination
- 717 chemistry facilitates metal ion release in the Psa permease. Nat Chem Biol. Nature Publishing Group;

**718** 2014;10:35–41.

- 35. Sahoo D, Sahoo S, Mohanty P, Sasmal S, Nayak PL. Chitosan: A new versatile bio-polymer for
  various applications. Des Monomers Polym. 2009;12:377–404.
- 721 36. Matsumoto M, Udomsinprasert W, Laengee P, Honsawek S, Patarakul K, Chirachanchai S. A Water-
- 722 Based Chitosan-Maleimide Precursor for Bioconjugation: An Example of a Rapid Pathway for an In Situ
- 723 Injectable Adhesive Gel. Macromol Rapid Commun. 2016;37:1618–22.
- 724 37. Martínez-Jothar L, Doulkeridou S, Schiffelers RM, Sastre Torano J, Oliveira S, van Nostrum CF, et
- al. Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization
- of nanoparticles for receptor targeting. J Control Release. Elsevier B.V; 2018;282:101–9.
- 38. Malhotra M, Tomaro-Duchesneau C, Saha S, Kahouli I, Prakash S. Development and characterization
- 728 of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int J Nanomedicine.
- **729** 2013;8:2041–52.
- 730 39. Kumirska J, Czerwicka M, Kaczyński Z, Bychowska A, Brzozowski K, Thöming J, et al. Application
- 731 of spectroscopic methods for structural analysis of chitin and chitosan. Mar Drugs. 2010;8:1567–636.
- 40. Esquivel R, Juárez J, Almada M, Ibarra J, Valdez MA. Synthesis and characterization of new
- thiolated chitosan nanoparticles obtained by ionic gelation method. Int J Polym Sci. 2015;2015.
- 41. Goulart C, Rodriguez D, Kanno AI, Silva JLSC, Leite LCC. Early pneumococcal clearance in mice
- 735 induced by systemic immunization with recombinant BCG PspA-PdT prime and protein boost correlates
- with cellular and humoral immune response in bronchoalveolar fluids (BALF). Vaccine X. The
- 737 Author(s); 2020;4:100049.
- 42. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother. 2004;58:168–
  739 72.
- 43. Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: Concepts,
- development and applications in drug delivery. J Control Release. Elsevier B.V; 2017;252:28–49.
- 44. Goycoolea FM, Valle-Gallego A, Stefani R, Menchicchi B, David L, Rochas C, et al. Chitosan-based
- 743 nanocapsules: Physical characterization, stability in biological media and capsaicin encapsulation. Colloid
- 744 Polym Sci. 2012;290:1423–34.

- 45. Calvo P, Alonso MJ, Sur C. Development of positively charged colloidal drug carriers : chitosan-
- coated polyester nanocapsules and submicron-emulsions. 1996;
- 46. Gradauer K, Vonach C, Leitinger G, Kolb D, Fröhlich E, Roblegg E, et al. Chemical coupling of
- thiolated chitosan to preformed liposomes improves mucoadhesive properties. Int J Nanomedicine.
- **749** 2012;7:2523–34.
- 47. Maruyama CR, Guilger M, Pascoli M, Bileshy-José N, Abhilash PC, Fraceto LF, et al. Nanoparticles
- 751 Based on Chitosan as Carriers for the Combined Herbicides Imazapic and Imazapyr. Sci Rep. Nature
- 752 Publishing Group; 2016;6.
- 48. Shrestha S, Wang B, Dutta P. Nanoparticle processing: Understanding and controlling aggregation.
- Adv Colloid Interface Sci. Elsevier B.V.; 2020;279:102162.
- 49. González-Aramundiz JV, Peleteiro M, González-Fernández Á, Alonso MJ, Csaba NS. Protamine
- 756 Nanocapsules for the Development of Thermostable Adjuvanted Nanovaccines. Mol Pharm.
- **757** 2018;15:5653–64.
- 50. Tuoriniemi J, Johnsson ACJH, Holmberg JP, Gustafsson S, Gallego-Urrea JA, Olsson E, et al.
- 759 Intermethod comparison of the particle size distributions of colloidal silica nanoparticles. Sci Technol
- 760 Adv Mater. IOP Publishing; 2014;15.
- 761 51. Menchicchi B, Fuenzalida JP, Bobbili KB, Hensel A, Swamy MJ, Goycoolea FM. Structure of
- 762 Chitosan determines its interactions with mucin. Biomacromolecules. 2014;15:3550–8.
- 763 52. Collado-González M, Espinosa YG, Goycoolea FM. Interaction between Chitosan and Mucin:
- Fundamentals and applications. Biomimetics. 2019;4:1–20.
- 765 53. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. High-throughput dynamic light
- scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem. Elsevier Inc.;
- 767 2010;399:141–3.
- 768 54. Raskin MM, Schlachet I, Sosnik A. Mucoadhesive nanogels by ionotropic crosslinking of chitosan- g
- -oligo(NiPAam) polymeric micelles as novel drug nanocarriers. Nanomedicine. 2016;11:217–33.
- 55. Szymańska E, Winnicka K. Stability of chitosan A challenge for pharmaceutical and biomedical
- 771 applications. Mar Drugs. 2015;13:1819–46.

- 56. Tonglairoum P, Brannigan RP, Opanasopit P, Khutoryanskiy V V. Maleimide-bearing nanogels as
- novel mucoadhesive materials for drug delivery. J Mater Chem B. 2016;4:6581–7.
- 57. Kaldybekov DB, Tonglairoum P, Opanasopit P, Khutoryanskiy V V. Mucoadhesive maleimide-
- functionalised liposomes for drug delivery to urinary bladder. Eur J Pharm Sci. Elsevier B.V;
- **776** 2018;111:83–90.
- 58. Tzankova V, Gorinova C, Kondeva-Burdina M, Simeonova R, Philipov S, Konstantinov S, et al.
- 778 In vitro and in vivo toxicity evaluation of cationic PDMAEMA-PCL-PDMAEMA micelles as a carrier of
- curcumin. Food Chem Toxicol. Elsevier Ltd; 2016;97:1–10.
- 780 59. Mellman I, Steinman RM. Minireview Dendritic Cells: Specialized and Regulated Antigen Processing
- 781 Machines cells are adept at endocytosis and express relatively low levels of surface MHC class I and II
- 782 products and costimu-latory molecules (e.g., CD86). Abundant MHC class II mol-. Cell. 2001;106:255–8.
- 60. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.
- 61. Al-Ashmawy GMZ. Dendritic Cell Subsets, Maturation and Function. Dendritic Cells. InTech; 2018.
- 785 62. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO)
- activity during dendritic-cell maturation. Blood. 2005;106:2375–81.
- 787 63. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by
- tryptophan catabolism. Cell Death Differ. 2002;9:1069–77.
- 789 64. Caulfield MJ. Endotoxin-induced T lymphocyte S N Vogel , M L Hilfiker and M J Caulfield
- 790 Information about subscribing to The Journal of Immunology is online at : 2019;
- 65. Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia.
  Infect Immun. 2009;77:568–75.
- 66. Dzopalic T, Rajkovic I, Dragicevic A, Colic M. The response of human dendritic cells to co-ligation
  of pattern-recognition receptors. Immunol Res. 2012;52:20–33.
- 795 67. Peleteiro M, Presas E, González-Aramundiz JV, Sánchez-Correa B, Simón-Vázquez R, Csaba N, et
- al. Polymeric nanocapsules for vaccine delivery: Influence of the polymeric shell on the interaction with
- the immune system. Front Immunol. 2018;9.